drugset
drugset / Trial / NCT05131841

Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC

NCT05131841 ↗

Phase 4 Unknown 60 enrolled Zhejiang Cancer Hospital Proswell Medical Corporation · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare pharmacokinetics Index of Cipterbin combined with Vinorelbine Injection every week or every three weeks in the treatment of patients with HER2-positive metastatic breast cancer

Timeline

Start
2021-01-04
Primary completion
2022-12-30
Completion
2022-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Inetetamab Monoclonal antibody — —
Subject Vinorelbine Small molecule — —

Indications

breast cancer